Walgreens Boots Alliance, Inc. and Travere Therapeutics, Inc.: A Detailed Gross Profit Analysis

Comparative Gross Profit Trends in Healthcare Giants

__timestampTravere Therapeutics, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 20142763222621569000000
Thursday, January 1, 20159770700026753000000
Friday, January 1, 201612903700029874000000
Sunday, January 1, 201715133200029162000000
Monday, January 1, 201815871900030792000000
Tuesday, January 1, 201917010400028159000000
Wednesday, January 1, 202019219500026077000000
Friday, January 1, 202122070600028067000000
Saturday, January 1, 202220442600028266000000
Sunday, January 1, 202313378800027072000000
Monday, January 1, 202426524000000
Loading chart...

Unleashing the power of data

A Tale of Two Companies: Walgreens Boots Alliance vs. Travere Therapeutics

In the ever-evolving landscape of the pharmaceutical and healthcare industry, Walgreens Boots Alliance, Inc. and Travere Therapeutics, Inc. present a fascinating study in contrasts. Over the past decade, Walgreens Boots Alliance has consistently demonstrated robust financial health, with gross profits peaking at approximately $30.8 billion in 2018. Despite a slight decline in recent years, their 2023 gross profit remains a formidable $27.1 billion, showcasing their resilience in a competitive market.

Conversely, Travere Therapeutics, a smaller player, has shown impressive growth, with gross profits increasing nearly eightfold from 2014 to 2021. However, 2023 saw a dip to $133.8 million, highlighting the volatility smaller companies often face. This analysis underscores the diverse strategies and challenges within the industry, offering valuable insights for investors and industry enthusiasts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025